



PATENT
Attorney Docket No. INL-036DV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Dahlbäck
SERIAL NO.: 09/912,947 GROUP NO.: 1634
FILING DATE: July 25, 2001 EXAMINER: Ethan C. Whisenant
TITLE: *Assays for Determining Anticoagulant Cofactor Activity*

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicant hereby makes of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☒ (2) after the period defined in (1) above but before the mailing date of a **final action** under 37 C.F.R. 1.113, a **notice of allowance** under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
- ☐ the requisite Statement is below, **OR**
- ☒ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein; or
- ☐ (3) after the period defined in (2) above but before the payment of the **issue fee**, **AND**

09/30/2005 MAHMED1 00000044 09912947

01 FC:1806

180.00 DP

02 FC:1806


- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Date: September 28, 2005
Reg. No. 51,551

Tel. No.: (617) 261-3198
Fax No.: (617) 261-3175

Respectfully submitted,



Fangli Chen, Ph.D.

Agent for Applicant

Kirkpatrick & Lockhart Nicholson

Graham LLP

75 State Street

Boston, Massachusetts 02109-1808



FORM PTO - 1449

FOURTH SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: INL-036DV

APPLICANT: Dahlbäck

SERIAL NO.: 09/912,947

FILING DATE: July 25, 2001 GROUP: 1634

U.S. PATENT DOCUMENTS

EXAM INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A27	5,910,576	6/08/1999	Bertina <i>et al.</i>			
	A28	6,518,016	2/11/2003	Bertina <i>et al.</i>			
	A29	6,558,913	5/06/2003	Bertina <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	C100	Alberts <i>et al.</i> , (1983), "Recombinant DNA Technology," <u>Molecular Biology of The Cell</u> , 185-196							
	C101	Jenny <i>et al.</i> , (1987), "Complete cDNA and derived amino acid sequence of human factor V," <u>Proc. Natl. Acad. Sci. USA</u> , 84:4846-4850							
	C102	Kalafatis <i>et al.</i> , (1993), "The Mechanism of Inactivation of Factor Va By Activated Protein C Involves Two Cleavages of the Heavy Chain of the Cofactor: (1) Arg ₅₀₅ And ARG ₃₀₆ ," <u>Thrombosis and Haemostasis</u> , 6:538-1455							
	C103	Kane <i>et al.</i> , (1986), "Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin," <u>Proc. Natl. Acad. Sci. USA</u> , 83:6800-6804							
	C104	Odegaard <i>et al.</i> , (1987), "Proteolysis Factor Va by Factor Xa and Activated Protein C*," <u>The Journal of Biological Chemistry</u> , 262(23):11233-11238							
	C105	Shen <i>et al.</i> , (1993), "The Serine Protease Cofactor Factor V Is Synthesized by Lymphocytes," <u>The Journal of Immunology</u> , 150(7):2992-3001							
	C106	Voorberg <i>et al.</i> , (1994), "Association of idiopathic venous thromboembolism with single point mutation at ARG ⁵⁰⁶ of factor V," 343:1535-1536							

EXAMINER

DATE CONSIDERED

BOS-900314 v1